NF-L Biomarker Program

About NeuroDex

NeuroDex is a private, pre-revenue diagnostics company founded in 2019, specializing in biomarker development for neurological disorders through its neuron-derived exosome (NDE) technology. The company offers a suite of biomarker services and panels targeting key pathological proteins (e.g., α-Syn, TDP-43, Tau) to support pharmaceutical partners in clinical trials and translational research. With a team led by CEO/CSO Erez Eitan and operations in Boston, NeuroDex positions itself at the intersection of advanced diagnostics and the growing precision neurology market, though it faces risks typical of early-stage biotechs, including platform validation and funding needs.

Therapeutic Areas